II42MR Imaging of PGAMcE6GdDOTA Conjugate in an Animal Tumor Model

Most anti-cancer drugs are lipophilic and the conjugation of lipophilic drugs to a polymeric carrier may also modify the in vivo behavior of the polymers. Mesochlorin e6 (Mce6) is a lipophilic photosentizer for photodynamic therapy.41,42 A paramagnetic poly(l-glutamic acid) Mce6 conjugate was prepared to investigate the pharmacokinetics, biodistribution and drug delivery efficiency of the PGA-Mce6 conjugate with contrast-enhanced MRI.43 The structure of the conjugate is shown in Figure 11.7. A PGA-1,6-hexanediamine-(Gd-DOTA) conjugate was also prepared from the same poly(l-glutamic acid) as a control. Mce6 content was 2.5 mol% in PGA-Mce6-1,6-hexanediamine-(Gd-DOTA) and Gd content was 20 and 29 mol% for PGA-Mce6-1,6-hexanediamine-(Gd-DOTA) and PGA-1,6-hexanediamine-(Gd-DOTA), respectively. The T1 relaxivity was 8.46 and 8.33 mM-1 s-1 for PGA-Mce6-1,6-hexa-nediamine-(Gd-DOTA) and PGA-1,6-hexanediamine-(Gd-DOTA), respectively. The small amount

FIGURE 11.7 The structure of PGA-Mce6-1,6-hexanediamine-(Gd-DOTA).

of Mce6 in PGA-Mce6-1,6-hexanediamine-(Gd-DOTA) significantly reduced the hydrodynamic volume and molecular weight distribution of the conjugate. The weight (Mw) and number (Mn) average molecular weights decreased from 101 and 49 kDa of PGA-1,6-hexadiamine-(Gd-DOTA) to 49 and 34 KDa for PGA-Mce6-1,6-hexadiamine-(Gd-DOTA). The lipophilic Mce6 may alter the conformation of the polymers, resulting in a smaller hydrodynamic volume for PGA-Mce6-1,6-hexa-diamine-(Gd-DOTA).

A contrast-enhanced MRI study demonstrated that PGA-Mce6-1,6-hexanediamine-(Gd-DOTA) had significantly different pharmacokinetics and biodistribution from PGA-1,6-hexanediamine-(Gd-DOTA) in female nu/nu athymic mice bearing human breast carcinoma MB-231 xenografts. Figure 11.8 shows coronal dynamic MR images of mice injected with PGA-Mce6-1,6-hexanedia-mine-(Gd-DOTA) and PGA-1,6-hexanediamine-(Gd-DOTA) at a dose of 0.07 mmol-Gd/kg. The conjugates demonstrated different dynamic contrast enhancement patterns in the heart and liver. PGA-Mce6-1,6-hexadiamine-(Gd-DOTA) had a strong contrast enhancement in the liver and relatively weak enhancement in the heart, whereas PGA-1,6-hexadiamine-(Gd-DOTA) exhibited

FIGURE 11.8 Coronal contrast-enhanced MR slice images for PGA-Mce6-(Gd-DOTA) conjugate and PGA-(Gd-DOTA) conjugate through the heart (b) before and at 5, 15, 30, 60, and 120 min post-injection.

strong enhancement in the heart and relatively weak enhancement in the liver. The conjugation of Mce6 significantly altered the pharmacokinetics and biodistribution of the poly(l-glutamic acid). The results indicated that PGA-Mce6-1,6-hexadiamine-(Gd-DOTA) had higher liver accumulation than PGA-1,6-hexadiamine-(Gd-DOTA). Consequently, it cleared from the blood circulation more rapidly than PGA-1,6-hexadiamine-(Gd-DOTA), which could also be attributed to the larger hydrodynamic volume of PGA-1,6-hexadiamine-(Gd-DOTA).

Diabetes Sustenance

Diabetes Sustenance

Get All The Support And Guidance You Need To Be A Success At Dealing With Diabetes The Healthy Way. This Book Is One Of The Most Valuable Resources In The World When It Comes To Learning How Nutritional Supplements Can Control Sugar Levels.

Get My Free Ebook

Post a comment